These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15600382)

  • 1. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.
    Huang TL; Chen JF
    Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of antipsychotic therapy on serum lipids: a comprehensive review.
    Meyer JM; Koro CE
    Schizophr Res; 2004 Sep; 70(1):1-17. PubMed ID: 15246458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study.
    Saari K; Koponen H; Laitinen J; Jokelainen J; Lauren L; Isohanni M; Lindeman S
    J Clin Psychiatry; 2004 Apr; 65(4):547-50. PubMed ID: 15119919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotic therapy and hyperlipidemia: a review.
    Koro CE; Meyer JM
    Essent Psychopharmacol; 2005; 6(3):148-57. PubMed ID: 15869022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine-induced severe mixed hyperlipidemia: a case report.
    Ahmed M; Griffin D; O'Toole R; McDonald C
    Gen Hosp Psychiatry; 2009; 31(1):93-6. PubMed ID: 19134516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should lipids be monitored during the first year of treatment with an atypical antipsychotic?
    Landry P; Benaliouad F
    Can J Psychiatry; 2003 Jun; 48(5):348-9. PubMed ID: 12866344
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes of plasma lipids during treatment with atypical antipsychotics.
    Rettenbacher MA; Ebenbichler C; Hofer A; Kemmler G; Baumgartner S; Edlinger M; Hummer M; Lechleitner M; Fleischhacker WW
    Int Clin Psychopharmacol; 2006 Nov; 21(6):369-72. PubMed ID: 17012984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine.
    Koskinen S; Kampman O; Solismaa A; Lyytikäinen LP; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Mononen N; Lehtimäki T; Leinonen E
    Pharmacogenomics; 2016 Dec; 17(18):1987-1997. PubMed ID: 27885961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
    Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
    Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia, antipsychotics and metabolic disease.
    Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.